Clinical Trial Update: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. [Phase 1]

View source ↗

Summary

A Phase 1 study of AZD9833, either alone or in combination, for ER-positive, HER2-negative advanced breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)

Snippet

Sponsor: AstraZeneca | Conditions: ER+ HER2- Advanced Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING